Evidence from preclinical models and at-risk patients suggests the earliest biochemical changes in the AD brain involve glucose hypometabolism and reduced oxygen flow [5, 6], oxidative stress [7–12], inflammation [13], and aberrant processing of amyloid precursor protein (APP) and tau [14–17]. The gene discussed is MAPT; the disease is Alzheimer disease.